The Trump administration is redoubling its efforts to phase out animal testing in drug development and seeking to develop new biotechnology methods instead to spur innovation in the pharmaceutical ...
David Reese believes that AI’s greatest impact will come from improving the thousands of human-led decisions. If Reese, the ...
Morning Overview on MSN
FDA urges alternatives to animal testing in early-stage drug development
The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward human-biology-based testing methods for monoclonal antibody programs. The ...
Swiss pharma Roche is staying in lockstep with Eli Lilly, expanding its artificial intelligence offerings and Nvidia ...
AAA Biotech’s Validated Antibodies, Recombinant Proteins, and ELISA Kits Power Breakthrough Research Across Drug ...
Artificial intelligence is booming across biopharma, with deployed tech taking aim at the industry’s biggest challenges: the significant risk of failure, high costs and long development timelines. And ...
Damian Garde joins Allison, Adam, and Elaine to discuss his article about Boris Nikolic, a well-connected biotech investor ...
BostonGene, developer of the leading AI foundation model for tumor and immune biology, today announced it has been named “Overall Immunology Company of the Year” in the fifth annual BioTech ...
This week on "The Readout LOUD," a conversation with biotech "godfather" Stelios Papadapolous live from #STATBreakthrough.
StockStory.org on MSN
A look back at drug development inputs & services stocks’ Q4 earnings: Repligen (NASDAQ:RGEN) vs the rest of the pack
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...
The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results